Granzyme B Antibodies

Granzyme B (GrB) is a single chain and single domain serine protease. It is a member of the chymotrypsin superfamily. The process of GrB glycosylation results in generation of a 32 kDa and a 35 kDa glycosylated forms of GrB. The 32 kDa GrB forms contain high mannose oligosaccharide moieties and accumulate in cytotoxic T lymphocytes (CTLs) after T cell receptor (TCR) stimulation. In contrast, the 35 kDa GrB forms, which possess only the complex oligosaccharide groups, are not stored in CTLs and instead they are secreted through the constitutive calcium-independent secretory pathway after TCR activation. GrB is the most abundant serine protease stored in secretory granules of CTLs and NK cells. GrB can be produced by plasmacytoid dendritic cells (pecs). GrB-induced cell death is a primary mechanism in cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to eliminate harmful target cells including allogeneic, virally infected and tumor cells. This mechanism implies activation of several pro-apoptotic pathways by direct proteolysis. The mannose 6-phosphate receptor has been identified as the plasma membrane receptor for GrB.


Clone: GB11 Isotype: IgG1 Mouse

The monoclonal antibody GB11 recognizes the human, mouse and rat Granzyme B.

Explore Granzyme B Antibodies

Content and Resources

Building IVDR compliant panels for haematological disorders wallchart Diagnostic purpose of the IVDR conjugated antibodies
IVDR: a new era for In-Vitro Diagnostic Medical Devices BEC Marseille IVDR team, in the framework of the IVDR Global program, has established and deployed a robust project plan to fulfill IVDR requirements of more than 230 IVD CE marked products for May 2022
How do I preserve sensitivity? Poster - How to preserve sensitivity
Immunophenotyping reference table - For haematopoietic malignancies Poster - Immunophenotyping reference table - For haematopoietic malignancies